Sodium glucose cotransporter-2 inhibitors and heart disease:Current perspectives  

作　　者：Sunetra Mondal Subhodip Pramanik Vibhu Ranjan Khare Cornelius James Fernandez Joseph M Pappachan 

机构地区：[1]Department of Endocrinology,NRS Medical College,Kolkata 700020,West Bengal,India [2]Department of Endocrinology,Neotia Getwel Multispecialty Hospitals,Siliguri 734010,West Bengal,India [3]Department of Endocrinology and Metabolism,Pilgrim Hospital,United Lincolnshire Hospitals NHS Trust,Boston PE219QS,United Kingdom [4]Department of Endocrinology and Metabolism,Lancashire Teaching Hospitals NHS Trust,Preston PR29HT,United Kingdom [5]Faculty of Science,Manchester Metropolitan University,Manchester M156BH,United Kingdom [6]Faculty of Biology,Medicine&Health,The University of Manchester,Manchester M139PL,United Kingdom

出　　处：《World Journal of Cardiology》2024年第5期240-259,共20页世界心脏病学杂志（英文版）（电子版）

摘　　要：Sodium glucose cotransporter-2 inhibitors(SGLT-2i)are antidiabetic medications with remarkable cardiovascular(CV)benefits proven by multiple randomised controlled trials and real-world data.These drugs are also useful in the prevention of CV disease(CVD)in patients with diabetes mellitus(DM).Although DM as such is a huge risk factor for CVD,the CV benefits of SGLT-2i are not just because of antidiabetic effects.These molecules have proven beneficial roles in prevention and management of nondiabetic CVD and renal disease as well.There are various molecular mechanisms for the organ protective effects of SGLT-2i which are still being elucidated.Proper understanding of the role of SGLT-2i in prevention and management of CVD is important not only for the cardiologists but also for other specialists caring for various illnesses which can directly or indirectly impact care of heart diseases.This clinical review compiles the current evidence on the rational use of SGLT-2i in clinical practice.

关 键 词：SGLT2 inhibitors SGLT2i Cardiovascular disease Heart failure Atherosclerotic cardiovascular disease Diabetic kidney disease 

分 类 号：R541.6[医药卫生—心血管疾病]